Immunizations and Allergy Injections

Immunization Requirements

• Required Vaccines

  • MMR: for students born after 1956, two doses required after 12 months of age

  • Tdap: single dose required for all students age 64 or younger

  • Meningococcal Vaccine (Menactra, Menveo): required after sixteenth birthday for all students age 21 or younger. If received initial dose before 16th birthday, booster is required. Students must present proof of vaccination, or may sign a waiver declining the vaccination.

  • Tuberculosis Test: a T-SPOT or QuantiFERON GOLD is required for any student who has resided or traveled outside of the U.S. for more than two weeks within the last five years or has other TB risk factors or if you answered “Yes” to any questions in the Tuberculosis Risk Assessment Questionnaire. Screening is REQUIRED upon arrival to Clemson, or documented proof of screening performed in the U.S. within the past 12 months. TB screenings performed outside of the U.S. and PPD skin test will not be accepted. As of January 2016, all students are required to complete the Tuberculosis Risk Assessment Questionnaire.

  Students with a prior positive tuberculin screening must bring a copy of a chest X-ray report (translated in English), within the last three months. Students who are receiving treatment for tuberculosis should bring copies of all treatment records, including medical notes, laboratory reports and X-rays.

• Recommended Vaccines
  • COVID (Moderna)
  • Flu
  • Human Papillomavirus (HPV)
  • Pneumococcal
  • Hepatitis A: series of two vaccines
  • Hepatitis B: series of three vaccines; can also be combined with Hepatitis A
  • Serogroup B Meningococcal (MenB)
  • Varicella: series of two vaccines

  The majority of the recommended vaccines are available at Redfern Health Center. Learn More About the Vaccines Above

• Exemptions/Waivers

  If completion of medical clearance requirements is contraindicated for medical reasons, approval of the healthcare provider is required along with documentation of the need for the exemption and signed Medical Exemption Form. To decline the meningococcal vaccination, sign and submit the Meningococcal Waiver.

  If a religious exemption is requested, complete the Religious Exemption Form.

• Human Papillomavirus (HPV) Vaccine

  9-valent (HPV 9) [Bivalent (HPV2) and Quadrivalent (HPV4) are no longer available]

  The HPV vaccines are indicated for prevention of cervical cancers in women and for use in both natal male and natal females for the prevention of pre-cancers and genital warts, anal cancer and anal intraepithelial dysplasia caused by HPV types included in the vaccine. No HPV or Pap test screening is required prior to administering vaccine; routine cervical cancer screening should continue according to current recommendations per the American College Health Association.

  Administer Human Papillomavirus (HPV) vaccine to natal females through age 26 and natal males through age 21 years (males aged 22 through 26 years may be vaccinated based on individual desire for protection and clinical decision).

  Adults with immunocompromising conditions (including HIV infection) through age 26 years: Administer 3-dose series at 0, 1-2, and 6 months. Men who have sex with men through age 26 years: administer 2 or 3-dose series depending on age at initial vaccination; if no history of HPV vaccine, administer 3-dose series at 0, 1-2 and 6 months.

  natal = gender assigned at birth

• Serogroup B Meningococcal Vaccine (MenB)

  MenB-4C (Bexsero, 2 dose series)

  MenB-Fhbp (Trumemba 2 or 3 dose series)

  Meningococcal disease is a serious illness caused by a bacteria. This disease can lead to meningitis, which is the infection of the lining of the brain and spinal cord. Meningococcal disease often occurs without any warning and may even infect people who are otherwise healthy. This vaccine may be administered to young adults age 16-23 for short-term protection. Other at-risk populations include people with certain medical conditions that weaken or affect the immune system and also people in proximity to other individuals who have contracted the disease.

  Meningococcal vaccines should not be given to pregnant or lactating females unless at an increased risk. There is also a precaution for individuals with a history of hypersensitivity to latex when receiving the MenB-4C (Bexsero) vaccine. MenB-4C and MenB-Fhbp are not interchangeable, so the same product must be used for all doses.

  For MenB-4C: 0-2 months

  For MenB-Fhbp: 0-2-6 months

• Pneumococcal Vaccine

  Pneumococcal Conjugate Vaccine (PCV13, Prevnar13)

  Pneumococcal Polysaccharide Vaccine-23 (PPSV23, Pneumovax 23)

  Pneumococcal disease is caused by bacteria that spreads from person to person through close and proximal contact. Pneumococcal disease can cause pneumonia, bacteremia or even meningitis. Children under the age of 2, adults over the age of 65 and others who exhibit unhealthy lifestyle habits are amongst those with the highest risk. PPSV23 protects against 23 types of pneumococcal bacteria; however, it will not prevent all pneumococcal disease. Anyone that has ever had a life-threatening allergic reaction to a dose of the PCV13 or PPSV23 vaccine, to an earlier pneumococcal vaccine called PCV7, or to any vaccine containing diphtheria toxoid (ex. DTaP) should not be administered PCV13 or PPSV23.